Leerink Partnrs Has Bearish Outlook for McKesson Q3 Earnings

McKesson Co. (NYSE:MCK - Free Report) - Leerink Partnrs decreased their Q3 2025 EPS estimates for shares of McKesson in a report issued on Thursday, December 5th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $8.13 per share for the quarter, down from their previous forecast of $8.87. The consensus estimate for McKesson's current full-year earnings is $32.73 per share. Leerink Partnrs also issued estimates for McKesson's Q4 2025 earnings at $9.86 EPS.

A number of other equities analysts have also weighed in on the stock. Leerink Partners decreased their price target on shares of McKesson from $665.00 to $630.00 and set an "outperform" rating on the stock in a report on Monday, October 7th. Robert W. Baird raised shares of McKesson from a "neutral" rating to an "outperform" rating and raised their target price for the company from $531.00 to $688.00 in a research note on Thursday, November 7th. Baird R W raised shares of McKesson from a "hold" rating to a "strong-buy" rating in a research note on Thursday, November 7th. Citigroup increased their target price on McKesson from $630.00 to $713.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Finally, StockNews.com upgraded McKesson from a "hold" rating to a "buy" rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, McKesson currently has an average rating of "Moderate Buy" and an average target price of $635.86.

McKesson Stock Down 2.1 %

Shares of MCK traded down $12.48 during mid-day trading on Monday, reaching $591.05. 551,941 shares of the company's stock were exchanged, compared to its average volume of 815,886. The company has a 50-day simple moving average of $554.83 and a two-hundred day simple moving average of $561.91. McKesson has a 52-week low of $431.35 and a 52-week high of $637.51. The company has a market cap of $75.03 billion, a price-to-earnings ratio of 30.98, a PEG ratio of 1.30 and a beta of 0.49.

McKesson (NYSE:MCK - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $7.07 earnings per share for the quarter, topping the consensus estimate of $6.88 by $0.19. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The company had revenue of $93.65 billion during the quarter, compared to analyst estimates of $89.33 billion. During the same quarter last year, the firm posted $6.23 earnings per share. McKesson's revenue was up 21.3% compared to the same quarter last year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date is Monday, December 2nd. McKesson's dividend payout ratio is presently 14.71%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Wolff Wiese Magana LLC increased its holdings in shares of McKesson by 742.9% in the third quarter. Wolff Wiese Magana LLC now owns 59 shares of the company's stock valued at $29,000 after buying an additional 52 shares in the last quarter. MidAtlantic Capital Management Inc. purchased a new stake in shares of McKesson during the third quarter valued at $29,000. RPg Family Wealth Advisory LLC acquired a new position in shares of McKesson in the 3rd quarter valued at $31,000. ORG Wealth Partners LLC purchased a new position in McKesson in the 3rd quarter worth about $40,000. Finally, Carmichael Hill & Associates Inc. acquired a new stake in McKesson during the 2nd quarter worth about $52,000. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.